SYK Earnings Prediction
The chart below shows how SYK performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SYK sees a -0.32% change in stock price 10 days leading up to the earnings, and a +1.43% change 10 days following the report. On the earnings day itself, the stock moves by +0.48%. This data can give you a slight idea of what to expect for the next quarter's release.
SYK Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
5.49B
11.92%
1.33%
Gross Margin
61.61%
0.34%
0.47%
Operating Margin
22.24%
8.86%
1.60%
Net Margin
15.18%
7.66%
-0.26%
EPS
2.16
20.00%
0.93%
No Data Available
SYK Earnings Analysis
Stryker Corporation Corporation (SYK.N) Earnings Conference Call
Positive
Organic Sales Growth: In the third quarter, we delivered robust organic sales growth of 11.5%.
Strong Growth Across Segments: Our performance included strong double-digit growth within Med Surg and Neurotechnology and nearly 10% growth in Orthopedics and Spine.
Quarterly EPS Growth: Our adjusted quarterly EPS of $2.87 reflects 16.7% growth compared to the third quarter of 2023.
2024 Guidance Update: We are narrowing our expectations for 2024 to the high end of our previously provided guidance ranges and now anticipate fully year organic sales growth of 9.5% to 10% and adjusted EPS of $12 to $12.10.
Double-Digit Organic Growth: Our strong results reflect double-digit organic growth from our medical, neuro cranial endoscopy, trauma and extremities, hips and knees businesses.
Negative
Adjusted Gross Margin Decline: Our adjusted gross margin of 64.5% was 20 basis points unfavorable from the third quarter of 2023.
R&D Spending Analysis: Our adjusted R&D spending was 6.6% of sales, which was 20 basis points lower than the third quarter of 2023.
SG&A Expense Reduction: Our adjusted SG&A was 33.2% of sales, which was 130 basis points lower than the third quarter of 2023 due to natural expense leverage combined with spending discipline somewhat offset by investments to support growth.
Net Adjusted Income Decline: Net adjusted other income and expense of $42 million for the quarter was $19 million lower than 2023, driven by favorable interest income on our invested cash balances.
Adjusted Effective Tax Rate: The third quarter of 2024 had an adjusted effective tax rate of 15.8%, reflecting the impact of geographic mix and certain discrete tax items.
SYK FAQs
How does SYK typically perform around its earnings report dates?
Is Stryker Corporation (SYK) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SYK Earning Call Sentiment
Stryker Corporation (SYK) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SYK.N
1.44%Positive
The earnings call summary and Q&A session indicate strong financial performance with 11.5% organic sales growth and a 16.7% increase in adjusted EPS. The guidance for 2024 is optimistic, with a minor negative impact from foreign exchange. Analysts' questions reflect confidence in the company's growth and innovation, especially in the medical division. Despite some competitive pressures and supply chain challenges, the overall sentiment is positive, with no major negative trends identified. The absence of a share repurchase program is a minor downside, but not enough to offset the positive outlook.